$ 55.59

-2.38(-4.1056%)

05-19 12:10

Galapagos NV - American Depositary Shares

Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. It operates through the Research and Development and Fee-for-Services segment. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.
最高:57.81今开:57.60成交量:35.18万股换手:0.54%
最低:55.44昨收:57.97成交额:1980.78万振幅:4.10%
52周最高:81.12量比:0.74市盈率(TTM):亏损市净率:1.31
52周最低:46.41委比:0.00%市盈率(静):亏损市销率:6.93
每股收益:-1.65股息(TTM):--每手股数:1总市值:36.49亿
每股净资产:42.34股息率(TTM):--最小价差:0.01总股本:6564.82万
机构持股:--Beta:--空头回补天数:--货币单位:USD
最新获投
暂无数据
最新动态
暂无数据
五力模型
财务指标
单位:美元
2018-06-30
2018-03-31
2017-12-31
2017-09-30
2017-06-30
流动资产
12.94亿
13.97亿
14.34亿
14.70亿
14.66亿
现金及短期投资
12.46亿
13.63亿
13.82亿
14.41亿
14.39亿
短期应收账款
3,941.88万
2,470.28万
5,018.02万
2,097.22万
1,784.05万
存货
31.17万
36.03万
33.50万
35.94万
36.27万
其他流动资产
827.33万
881.80万
65.20万
820.21万
791.09万
非流动资产
1.13亿
1.16亿
1.11亿
1.03亿
9,511.96万
厂房及设备净资产
2,084.54万
2,087.18万
2,004.38万
1,806.28万
1,768.54万
项目总投资及垫款
135.20万
142.42万
349.67万
143.64万
129.68万
长期应收票据
8,355.81万
8,521.02万
--
7,789.99万
6,984.96万
无形资产
163.81万
314.23万
299.60万
88.31万
97.97万
递延所得税资产
231.17万
243.39万
237.52万
231.36万
223.21万
其他资产
292.59万
268.35万
8,210.47万
288.81万
307.61万
合计总资产
14.06亿
15.13亿
15.45亿
15.74亿
15.61亿
流动负债
2.88亿
2.75亿
2.06亿
1.83亿
1.49亿
短期债务(含部分LTD)
--
--
1.08万
2.72万
4.22万
应付账款
8,072.56万
6,844.98万
5,658.41万
5,726.22万
4,184.22万
应付所得税
100.64万
106.01万
103.87万
98.71万
116.11万
其他流动负债
2.06亿
2.06亿
1.49亿
1.24亿
1.06亿
非流动负债
8,418.27万
1.31亿
1.23亿
1.65亿
1.92亿
长期负债
--
--
--
--
--
拨备风险及费用
443.32万
458.12万
437.93万
448.05万
424.28万
递延所得税负债
--
--
--
--
--
其他负债
7,974.95万
1.27亿
1.19亿
1.61亿
1.88亿
合计总负债
3.72亿
4.06亿
3.29亿
3.48亿
3.41亿
股东权益合计
10.34亿
11.06亿
12.15亿
12.26亿
12.19亿
非股权储备
--
--
--
--
--
优先股-账面价值
0.00
0.00
0.00
0.00
0.00
普通股权益(合计)
10.34亿
11.06亿
12.15亿
12.26亿
12.19亿
累计少数股东权益
--
--
--
--
--
权益总额
10.34亿
11.06亿
12.15亿
12.26亿
12.19亿
负债与股东权益合计
14.06亿
15.13亿
15.45亿
15.74亿
15.61亿
每股账面价值
20.14
21.59
23.86
24.09
23.97
每股账面价值-有形
20.11
21.53
23.80
24.07
23.95
单位:美元
2018-06-30
2018-03-31
2017-12-31
2017-09-30
2017-06-30
营业总收入
5,915.79万
4,658.79万
4,651.25万
3,188.59万
3,011.11万
-营业成本
5,915.79万
4,658.79万
4,651.25万
3,188.59万
3,011.11万
毛利
--
--
--
--
--
-销售管理及行政费用
1.05亿
9,300.86万
8,982.87万
7,325.89万
6,009.25万
-其他运营费用
--
--
--
--
--
计息税前利润
-4,895.56万
-4,789.19万
-4,459.00万
-4,263.56万
-3,120.45万
+非经营收入(支出)
2,311.49万
1,049.69万
1,371.05万
914.04万
841.52万
-非经常性支出
--
--
--
--
--
-利息支出
--
834.99万
447.96万
974.15万
1,710.43万
税前净利润
-2,583.96万
-4,574.48万
-3,535.91万
-4,323.68万
-3,974.71万
-所得税
8.93万
7.62万
4.27万
8.17万
10.29万
+其他税后调整
0.00
0.00
0.00
0.00
0.00
+联署公司盈利权益
--
--
--
--
--
合并净利润
-2,592.89万
-4,582.10万
-3,540.18万
-4,331.84万
-3,985.00万
-少数股东权益开支
--
--
--
--
--
净利润
-2,592.89万
-4,582.10万
-3,540.18万
-4,331.84万
-3,985.00万
-优先股股息
--
--
--
--
--
一般可用收入净利润
-2,592.89万
-4,582.10万
-3,540.18万
-4,331.84万
-3,985.00万
每股基本收益
-0.50
-0.90
-0.70
-0.85
-0.83
摊薄每股收益
-0.50
-0.90
-0.70
-0.85
-0.83
息税折旧摊销前利润
-4,599.39万
-4,642.08万
-4,331.62万
-4,137.30万
-2,998.14万
单位:美元
2017-12-31
2016-12-31
2015-12-31
2014-12-31
净收益
-1.32亿
5,961.68万
-1.31亿
4,388.34万
+折旧损耗及摊稍
488.31万
461.60万
375.47万
614.30万
+递延税及投资税减免
-2.28万
--
--
--
+其他经营基金
4,899.44万
-5,932.32万
3,797.69万
-8,319.35万
营运资金
-7,800.04万
490.96万
-8,895.28万
-3,316.72万
+特别项目
--
--
--
--
+营运资金变动
-8,955.35万
2.59亿
-3,751.56万
-6,666.61万
经营现金流
-1.68亿
2.64亿
-1.26亿
-9,983.33万
资本支出
-847.51万
-528.71万
-735.59万
-370.51万
收购所得净资产
--
--
--
--
固定资产和业务出售收入
7,977.13
--
12.14万
1.73亿
投资买卖净额
42.28万
-303.54万
--
--
非现金项目
741.87万
27.93万
249.21万
-980.71万
投资现金流
-62.56万
-804.32万
-474.24万
1.59亿
发放现金股利
--
--
--
--
股本变动
4.03亿
4.37亿
3.00亿
585.36万
发行/削减债务净额
-7.41万
-5.41万
-4.75万
-28.54万
其他融资基金
--
--
--
--
筹资现金流
4.03亿
4.37亿
3.00亿
556.82万
汇率影响
-3,168.97万
531.47万
13.13万
35.81万
杂项基金
--
--
--
--
现金净流动
2.03亿
6.99亿
1.68亿
6,545.57万
自由现金流
-1.74亿
2.59亿
-1.33亿
-1.03亿
公司高管
Werner Cautreels
Presently, Werner Cautreels occupies the position of President, Chief Executive Officer & Director at Selecta Biosciences, Inc. He is also on the board of Galapagos NV. Dr. Cautreels previously held the position of General Manager-Pharmaceuticals at Solvay SA, Global Chief Executive Officer at Solvay Pharmaceuticals SA, Vice President-Scientific Affairs at Sanofi-Aventis U.S. LLC, Senior Vice President-Research & Development at Nycomed Amersham Medical Systems, Principal at Sterling Winthrop, Inc. and President of Belgian Luxembourg Chamber of Commerce for Russia & Belarus. He received a doctorate, a graduate degree and an undergraduate degree from the University of Antwerp and an MBA from Harvard Business School.
Raj B. Parekh
Founder of Oxford GlycoSciences Plc and Arrakis Therapeutics, Inc., Raj B. Parekh is a British businessperson who has been at the helm of 5 different companies and occupies the position of Chairman for Galapagos NV and General Partner for Advent Venture Partners LLP, General Partner at Advent Life Sciences LLP (a subsidiary of Advent Venture Partners LLP). He is also General Partner at Advent Life Sciences LLP and on the board of 17 other companies. In the past he was Non-Executive Chairman at Chroma Therapeutics Ltd., Chairman for CoCo Therapeutics Ltd., CEO, Chief Scientific Officer & Senior VP-Research at Oxford GlycoSciences Plc and Chief Executive Officer & Director at Biocartis SA. Dr. Parekh received a graduate degree, an undergraduate degree and a doctorate from the University of Oxford.
Onno van de Stolpe
Founder of Galapagos NV, Onno van de Stolpe currently is Chief Executive Officer & Executive Director at this company. He is also on the board of Galapagos Biotech Ltd. and Institute For Human Organ & Disease Model Technologies. He previously occupied the position of Principal at Netherlands Foreign Investment Agency, Chief Executive Officer for Galapagos Genomics NV, Managing Director at Molecular Probes, Inc., Manager-Business Development at Mogen International Nv and Managing Director-Genomics Division at Introgene BV. Dr. Van de Stolpe received a graduate degree from Wageningen University.
Katrine S. Bosley
Katrine S. Bosley holds the position of Chairman for Genocea Biosciences, Inc. and President, Chief Executive Officer & Director at Editas Medicine, Inc. She is also on the board of Galapagos NV and Biotechnology Innovation Organization. In the past she held the position of Director-Decision Support at Biogen, Inc., President & Chief Executive Officer of Avila Therapeutics, Inc., Vice President-Business Development for Adnexus, President-Celgene Avilomics Research at Celgene LLC and Principal at Alkermes, Inc. Ms. Bosley received an undergraduate degree from Cornell University.
Harrold van Barlingen
Dr. Harrold van Barlingen is the Managing Director and Founder of Thuja Capital. Prior to founding Thuja Capital, he headed the life science effort of AlpInvest Partners managing a portfolio of over 30 companies. Harrrold joined AlpInvest Partners in 2001, from the Boston Consulting Group ('BCG'), where he worked as a consultant in management and strategy. Before BCG, Harrold was acting head of the continental activities of the Lewin Group (a Quintiles subsidiary), an international firm specialized in the field of health economy. Harrold holds a Master of Science degree in Medical Biology and a Ph.D. in Medicine, both from the University of Utrecht. From 1991-1992 he was a visiting scientist at the University of Chicago, USA. Harrold is the author of a wide-variety of peer-reviewed scientific and pharmaco-economics papers. Harrold represents AlpInvest Partners at the boards of Avantium, BioXell, DrugAbuse Sciences, Curacyte, Galapagos and Omrix pharmaceuticals.
Werner Cautreels
Presently, Werner Cautreels occupies the position of President, Chief Executive Officer & Director at Selecta Biosciences, Inc. He is also on the board of Galapagos NV. Dr. Cautreels previously held the position of General Manager-Pharmaceuticals at Solvay SA, Global Chief Executive Officer at Solvay Pharmaceuticals SA, Vice President-Scientific Affairs at Sanofi-Aventis U.S. LLC, Senior Vice President-Research & Development at Nycomed Amersham Medical Systems, Principal at Sterling Winthrop, Inc. and President of Belgian Luxembourg Chamber of Commerce for Russia & Belarus. He received a doctorate, a graduate degree and an undergraduate degree from the University of Antwerp and an MBA from Harvard Business School.
Raj B. Parekh
Founder of Oxford GlycoSciences Plc and Arrakis Therapeutics, Inc., Raj B. Parekh is a British businessperson who has been at the helm of 5 different companies and occupies the position of Chairman for Galapagos NV and General Partner for Advent Venture Partners LLP, General Partner at Advent Life Sciences LLP (a subsidiary of Advent Venture Partners LLP). He is also General Partner at Advent Life Sciences LLP and on the board of 17 other companies. In the past he was Non-Executive Chairman at Chroma Therapeutics Ltd., Chairman for CoCo Therapeutics Ltd., CEO, Chief Scientific Officer & Senior VP-Research at Oxford GlycoSciences Plc and Chief Executive Officer & Director at Biocartis SA. Dr. Parekh received a graduate degree, an undergraduate degree and a doctorate from the University of Oxford.
Onno van de Stolpe
Founder of Galapagos NV, Onno van de Stolpe currently is Chief Executive Officer & Executive Director at this company. He is also on the board of Galapagos Biotech Ltd. and Institute For Human Organ & Disease Model Technologies. He previously occupied the position of Principal at Netherlands Foreign Investment Agency, Chief Executive Officer for Galapagos Genomics NV, Managing Director at Molecular Probes, Inc., Manager-Business Development at Mogen International Nv and Managing Director-Genomics Division at Introgene BV. Dr. Van de Stolpe received a graduate degree from Wageningen University.
Katrine S. Bosley
Katrine S. Bosley holds the position of Chairman for Genocea Biosciences, Inc. and President, Chief Executive Officer & Director at Editas Medicine, Inc. She is also on the board of Galapagos NV and Biotechnology Innovation Organization. In the past she held the position of Director-Decision Support at Biogen, Inc., President & Chief Executive Officer of Avila Therapeutics, Inc., Vice President-Business Development for Adnexus, President-Celgene Avilomics Research at Celgene LLC and Principal at Alkermes, Inc. Ms. Bosley received an undergraduate degree from Cornell University.
Harrold van Barlingen
Dr. Harrold van Barlingen is the Managing Director and Founder of Thuja Capital. Prior to founding Thuja Capital, he headed the life science effort of AlpInvest Partners managing a portfolio of over 30 companies. Harrrold joined AlpInvest Partners in 2001, from the Boston Consulting Group ('BCG'), where he worked as a consultant in management and strategy. Before BCG, Harrold was acting head of the continental activities of the Lewin Group (a Quintiles subsidiary), an international firm specialized in the field of health economy. Harrold holds a Master of Science degree in Medical Biology and a Ph.D. in Medicine, both from the University of Utrecht. From 1991-1992 he was a visiting scientist at the University of Chicago, USA. Harrold is the author of a wide-variety of peer-reviewed scientific and pharmaco-economics papers. Harrold represents AlpInvest Partners at the boards of Avantium, BioXell, DrugAbuse Sciences, Curacyte, Galapagos and Omrix pharmaceuticals.
高管交易状态
暂无数据
持股状况
持有者 持有份额 持股比例 份额变化 变化率 报告日期
Alps Advisors Inc
73389
0.14%
5234
7.68%
2018-06-30
Fidelity Management and Research Company
802378
1.56%
-1038208
-56.41%
2018-06-30
Orbimed Advisors, LLC
486990
0.95%
--
--
2018-06-30
BlackRock Inc
308565
0.60%
-16255
-5.00%
2018-06-30
Baker Bros Advisors LP
259894
0.51%
--
--
2018-06-30
Wellington Management Company LLP
251988
0.49%
-1140
-0.45%
2018-06-30
Close Finsbury Asset Management Limited
169000
0.33%
--
--
2018-05-31
Rock Springs Capital Management LP
185000
0.36%
--
--
2018-06-30
Renaissance Technologies Corp
175030
0.34%
-52070
-22.93%
2018-06-30
Deerfield Management Co
165000
0.32%
35000
26.92%
2018-06-30
Perceptive Advisors LLC
150875
0.29%
-55430
-26.87%
2018-06-30
Credit Suisse First Boston (CSFB)
125282
0.24%
-57087
-31.30%
2018-06-30
Peregrine Capital Management Inc
102136
0.20%
-15075
-12.86%
2018-03-31
DORSEY WRIGHT & ASSOCIATES
98544
0.20%
8186
9.06%
2018-06-30
Tekla Capital Management LLC
86815
0.17%
-8820
-9.22%
2018-06-30
Alberta Investment Management Corp
70000
0.14%
--
--
2018-03-31
Federated Global Inv Mgmt Corp
1292214
2.52%
-47186
-3.52%
2018-03-31
Sands Capital Management, LLC
1843486
3.59%
-35200
-1.87%
2018-06-30
Van Herk Investments B V
5133958
10.02%
676811
15.18%
2018-06-08
Gilead Sciences Inc
6760701
13.27%
6760701
--
2017-12-07
Deutsche Bank AG
68655
0.13%
19724
40.31%
2018-03-31
Farallon Capital Management, L.L.C.
308260
0.60%
18260
6.30%
2018-03-31
Wells Fargo Funds Management LLC
74329
0.15%
2
--
2018-05-31
EcoR1 Capital, LLC
110384
0.22%
-130392
-54.15%
2017-12-31
Goldman Sachs Asset Management LP
94164
0.18%
-25004
-20.98%
2017-12-31
Morgan Stanley Smith Barney LLC
70382
0.14%
16164
29.81%
2017-12-31
BlackRock Fund Advisors
133104
0.26%
-474
-0.35%
2018-03-21
BlackRock Advisors LLC
104600
0.21%
--
--
2018-02-28
JANE STREET GROUP, LLC
73254
0.14%
-45885
-38.51%
2017-09-30
Clough Capital Partners, LP
72453
0.14%
2600
3.72%
2017-09-30
Cormorant Asset Management, LLC
300000
0.59%
--
--
2017-06-30
Atika Capital Management LLC
52000
0.11%
31000
147.62%
2016-09-30
Eventide Asset Management, LLC
52000
0.11%
--
--
2016-09-30
Dafna Capital Management LLC
66068
0.14%
2500
3.93%
2016-09-30
Adage Capital Partners Gp LLC
85000
0.18%
-150000
-63.83%
2016-09-30
持有者 持有份额 持股比例 份额变化 变化率 报告日期
JHFunds2 Small Cap Growth 1
13890
0.03%
--
--
2018-07-31
Federated Kaufmann Large Cap A
460210
0.90%
89210
24.05%
2018-06-30
Old Westbury Large Cap Strategies
220000
0.43%
--
--
2018-04-30
Federated Kaufmann Small Cap A
176800
0.34%
79900
82.46%
2018-06-30
Fidelity Advisor
131082
0.26%
-46347
-26.12%
2018-07-31
Sands Capital Global Growth Inst
141500
0.28%
-6000
-4.07%
2018-04-30
iShares Nasdaq Biotechnology
99465
0.23%
-189
-0.19%
2018-09-12
BlackRock Health Sciences Opps Inv A
104600
0.20%
--
--
2018-07-31
ALPS Medical Breakthroughs ETF
92509
0.21%
--
--
2018-09-14
Wells Fargo Small Company Growth Admin
78577
0.15%
33
0.04%
2018-07-31
AdvisorShares WCM/BNY MlnFcsd GR ADR ETF
49656
0.11%
-680
-1.35%
2018-09-14
Hartford Small Company HLS IA
43396
0.08%
--
--
2018-07-31
Hartford Small Company A
38340
0.07%
--
--
2018-07-31
Eventide Healthcare & Life Sciences A
40000
0.08%
--
--
2018-06-30
JHVIT Small Cap Growth NAV
31422
0.06%
--
--
2018-07-31
Putnam Multi-Cap Value A
20900
0.04%
--
--
2018-06-30
Federated Kaufmann II Svc
20202
0.04%
-1156
-5.41%
2018-06-30
BNY Mellon Small Cap Multi-Strategy M
16790
0.03%
--
--
2018-07-31
Fidelity
577139
1.12%
-47810
-7.65%
2018-07-31
Federated Kaufmann R
753112
1.47%
-49844
-6.21%
2018-06-30
Goldman Sachs Small/Mid Cap Growth A
87260
0.17%
-23384
-21.13%
2017-12-31
Fidelity VIP Health Care Inv
48200
0.10%
--
--
2016-12-31
Tekla Life Sciences Investors
113896
0.25%
--
--
2016-09-30
Eaton Vance Worldwide Health Sciences Fu
279800
0.70%
--
--
2015-09-30
Goldman Sachs Small/Mid Cap Growth Fund
295544
0.80%
133650
82.50%
2015-09-30
Fidelity® Series Growth Company Fund
296300
0.80%
--
--
2015-09-30
Fidelity® OTC Portfolio
786600
2.00%
--
--
2015-09-30
Federated Kaufmann Fund
956807
2.50%
--
--
2015-09-30
Fidelity® Growth Company Fund
1064441
2.70%
-11600
-1.10%
2015-09-30
Fidelity Advisor® Biotechnology Fund
253629
0.60%
--
--
2015-09-30
Worldwide Healthcare
233100
0.60%
--
--
2015-07-31
CamGestion Euro Mid Cap
132575
0.40%
132575
--
2015-03-31
Federated Kaufmann Small Cap Fund
122066
0.30%
--
--
2015-09-30
Hartford Small Company HLS Fund
113801
0.30%
-18806
-14.20%
2015-09-30
Franklin Biotechnology Discovery
91200
0.20%
--
--
2015-07-31
Hartford Small Company Fund
73702
0.20%
-12069
-14.10%
2015-09-30
RS Small Cap Growth Fund
64160
0.20%
-144980
-69.30%
2015-09-30
Fidelity® Select Biotechnology Portfolio
1138988
2.90%
--
--
2015-09-30